Through this agreement, the two companies will cooperate in the research and development of a treatment for meniscal cartilage injuries in the knee, based on autologous mesenchymal stem cells.
The main areas of collaboration include: ▲ clinical research and regenerative medical treatments in advanced regenerative medicine ▲ development of advanced biopharmaceuticals ▲ establishment of GMP and cell processing facilities ▲ education and training of research personnel.
Avantrex possesses proprietary technology for “biomaterial-based stem cell self-assembly.” Based on this technology, the company is developing next-generation fillers and biomaterial-based medical devices that induce the regeneration of various tissues damaged by arthritis.
A Pharmicell representative stated, “We will establish a close cooperative system with Avantrex throughout the entire process from advanced regenerative medicine clinical research to commercialization, utilizing our advanced GMP manufacturing facilities, production infrastructure based on human cell management, skilled professionals, and established testing and evaluation systems.”
Recently, Pharmicell expanded the range of cells handled under its human cell management business to seven types and is actively expanding its CDMO business domain to include advanced regenerative medicine institutions and cell therapy product R&D companies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
